Pub Date : 2024-01-01DOI: 10.46439/breastcancer.4.021
Vincent Sollars, Alexandria Chapman, Nicole R Liang, Seth Myers
"What are the mechanisms driving tumor evolution under the selective pressure of chemotherapeutics?" The emerging importance of epigenetic gene regulation in cancer progression necessitates not only our understanding of which genes are potential targets but also what mechanisms are employed in targeting those genes. Understanding the mechanisms that promote the evolution of the normal genome and epigenome is central to understanding how cancer cells adapt to chemotherapy. Our previous investigations have shown that heat shock protein 90 (HSP90) has a critical role in epigenetic gene regulation through histone acetylation and phenotypic plasticity. We recently extended these results in an A549 lung cancer model to test the role of HSP90 in the plasticity of cells regarding multi-drug resistance and epithelial-to-mesenchymal transition phenotypes. HSP90 is over-expressed in multiple cancers with poor prognosis. We propose that inhibition of HSP90 results in lower phenotypic plasticity of cancer cells making them more susceptible to chemotherapeutic intervention. Here we review the context of our results in the broader field of evolution of these phenotypes.
{"title":"Investigating the role of HSP90 in cancer cell phenotypic plasticity.","authors":"Vincent Sollars, Alexandria Chapman, Nicole R Liang, Seth Myers","doi":"10.46439/breastcancer.4.021","DOIUrl":"10.46439/breastcancer.4.021","url":null,"abstract":"<p><p><i>\"What are the mechanisms driving tumor evolution under the selective pressure of chemotherapeutics?\"</i> The emerging importance of epigenetic gene regulation in cancer progression necessitates not only our understanding of which genes are potential targets but also what mechanisms are employed in targeting those genes. Understanding the mechanisms that promote the evolution of the normal genome and epigenome is central to understanding how cancer cells adapt to chemotherapy. Our previous investigations have shown that heat shock protein 90 (HSP90) has a critical role in epigenetic gene regulation through histone acetylation and phenotypic plasticity. We recently extended these results in an A549 lung cancer model to test the role of HSP90 in the plasticity of cells regarding multi-drug resistance and epithelial-to-mesenchymal transition phenotypes. HSP90 is over-expressed in multiple cancers with poor prognosis. We propose that inhibition of HSP90 results in lower phenotypic plasticity of cancer cells making them more susceptible to chemotherapeutic intervention. Here we review the context of our results in the broader field of evolution of these phenotypes.</p>","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"4 1","pages":"5-10"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11448696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-06DOI: 10.46439/breastcancer.3.019
Manh Tien Tran
{"title":"Metastatic breast cancer-derived exosomes and osteoclast-mediated bone metastasis","authors":"Manh Tien Tran","doi":"10.46439/breastcancer.3.019","DOIUrl":"https://doi.org/10.46439/breastcancer.3.019","url":null,"abstract":"","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"296 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72504281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-06DOI: 10.46439/breastcancer.2.011
Amar S, Lieberman S, Biderman A, Lahad A, Feinsilver T
Israeli Jewish women of Ashkenazi ancestry have a high BRCA mutation carrier rate. Therefore, recently, Israel included free genetic testing among all Jewish women with Ashkenazi ancestry, 25 yrs. and older in its public health system. The aim of this study was to assess the intention of eligible women to be tested for BRCA mutations, and to find factors that may affect their decision. We distributed an online survey to a panel of participants in a commercial research institute. The survey included socio-demographic characteristics, attitudes towards preventive actions, views related to benefits and limitations of performing the BRCA test, worry regarding cancer morbidity, knowledge about breast cancer morbidity and hereditary breast cancer genetics. The survey concluded with a question regarding the woman’s interest in undergoing the BRCA test. The results showed that among the 506 respondents, 250 (49%) were interested in BRCA testing, 42 (8%) objected and 214 (43%) were undecided. In comparing the undecided to the other groups, we found that most presented a positive attitude towards screening tests and preventive medicine, they showed acceptable knowledge about the proposed test, and yet were interested in learning and further expanding the knowledge and the consequences of doing the test. Most respondents of all groups expressed concern of breast cancer morbidity and were reluctant to perform the test for reasons of reducing uncertainty, implications for children and implications for their own health. Within all groups, many women expressed their desire to consult with a medical professional about the test. We conclude that aiming to improve the performance of BRCA genetic testing, women need a thorough explanation about its implications. The main way to inform them would be by medical professionals, especially in primary care. This implies that front line nurses and physicians need to become more knowledgeable and committed to this subject.
{"title":"A new population screening program for BRCA mutations in Israel – Attitudes and barriers among Ashkenazi Jewish women","authors":"Amar S, Lieberman S, Biderman A, Lahad A, Feinsilver T","doi":"10.46439/breastcancer.2.011","DOIUrl":"https://doi.org/10.46439/breastcancer.2.011","url":null,"abstract":"Israeli Jewish women of Ashkenazi ancestry have a high BRCA mutation carrier rate. Therefore, recently, Israel included free genetic testing among all Jewish women with Ashkenazi ancestry, 25 yrs. and older in its public health system. The aim of this study was to assess the intention of eligible women to be tested for BRCA mutations, and to find factors that may affect their decision.\u0000\u0000We distributed an online survey to a panel of participants in a commercial research institute. The survey included socio-demographic characteristics, attitudes towards preventive actions, views related to benefits and limitations of performing the BRCA test, worry regarding cancer morbidity, knowledge about breast cancer morbidity and hereditary breast cancer genetics. The survey concluded with a question regarding the woman’s interest in undergoing the BRCA test.\u0000\u0000The results showed that among the 506 respondents, 250 (49%) were interested in BRCA testing, 42 (8%) objected and 214 (43%) were undecided. In comparing the undecided to the other groups, we found that most presented a positive attitude towards screening tests and preventive medicine, they showed acceptable knowledge about the proposed test, and yet were interested in learning and further expanding the knowledge and the consequences of doing the test. Most respondents of all groups expressed concern of breast cancer morbidity and were reluctant to perform the test for reasons of reducing uncertainty, implications for children and implications for their own health.\u0000\u0000Within all groups, many women expressed their desire to consult with a medical professional about the test. We conclude that aiming to improve the performance of BRCA genetic testing, women need a thorough explanation about its implications. The main way to inform them would be by medical professionals, especially in primary care. This implies that front line nurses and physicians need to become more knowledgeable and committed to this subject.","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81971319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-06DOI: 10.46439/breastcancer.3.017
Aradhya Nigam, B. Untch, A. Shaha
The recent development of the International Medullary Thyroid Cancer Grading System (IMTCGS) provided clinicians with a tool to predict for disease outcomes after undergoing resection based on histologic features. However, its impact on the clinical management of patients is still under investigation. Utilizing the IMTCGS, we evaluated the association of grade with postoperative surveillance markers. High-grade tumors, when compared to low-grade, had a significantly more rapid calcitonin doubling time with a vast majority of high-grade patients having doubling times <2 years. While these findings reaffirmed the poor recurrence and mortality outcomes observed in high-grade patients, we found that high-grade patients with rapid calcitonin doubling times were particularly at risk for poor local control and survival outcomes.These findings demonstrate the importance of close clinical follow-up of patients with high-grade disease and further support the determination tumor grade and calcitonin doubling times in MTC patients after resection. In addition, the study supports the use of MTC grading as an important variable for future management of MTC patients. This could lay the foundation for better understanding of neuroendocrine carcinomas of the breast.
{"title":"Tumor grade as a novel predictor of outcomes in medullary thyroid cancer","authors":"Aradhya Nigam, B. Untch, A. Shaha","doi":"10.46439/breastcancer.3.017","DOIUrl":"https://doi.org/10.46439/breastcancer.3.017","url":null,"abstract":"The recent development of the International Medullary Thyroid Cancer Grading System (IMTCGS) provided clinicians with a tool to predict for disease outcomes after undergoing resection based on histologic features. However, its impact on the clinical management of patients is still under investigation. Utilizing the IMTCGS, we evaluated the association of grade with postoperative surveillance markers. High-grade tumors, when compared to low-grade, had a significantly more rapid calcitonin doubling time with a vast majority of high-grade patients having doubling times <2 years. While these findings reaffirmed the poor recurrence and mortality outcomes observed in high-grade patients, we found that high-grade patients with rapid calcitonin doubling times were particularly at risk for poor local control and survival outcomes.These findings demonstrate the importance of close clinical follow-up of patients with high-grade disease and further support the determination tumor grade and calcitonin doubling times in MTC patients after resection. In addition, the study supports the use of MTC grading as an important variable for future management of MTC patients. This could lay the foundation for better understanding of neuroendocrine carcinomas of the breast.","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80422003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-06DOI: 10.46439/breastcancer.2.012
Jenna Shepherd, Mairi Fuller, Sue Rodwell, Rachel Moir, Beatrix Elsberger, Yazan A. Masannat
{"title":"Loss of breast reconstruction services during the COVID-19 pandemic: Negative impact on patient quality of life and wellbeing","authors":"Jenna Shepherd, Mairi Fuller, Sue Rodwell, Rachel Moir, Beatrix Elsberger, Yazan A. Masannat","doi":"10.46439/breastcancer.2.012","DOIUrl":"https://doi.org/10.46439/breastcancer.2.012","url":null,"abstract":"","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"68 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136012191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-06DOI: 10.46439/breastcancer.2.013
María José Hernández-Leal, M. Pérez-Lacasta, M. Carles-Lavila
{"title":"Advances in shared decision-making for breast cancer screening in Spain","authors":"María José Hernández-Leal, M. Pérez-Lacasta, M. Carles-Lavila","doi":"10.46439/breastcancer.2.013","DOIUrl":"https://doi.org/10.46439/breastcancer.2.013","url":null,"abstract":"","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90535955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-06DOI: 10.46439/breastcancer.2.015
Subhanki Dhar, Tania Sarkar, G. Sa
{"title":"Neoangiogenesis and immune-regulation: Two armour of VEGF in the tumor microenvironment","authors":"Subhanki Dhar, Tania Sarkar, G. Sa","doi":"10.46439/breastcancer.2.015","DOIUrl":"https://doi.org/10.46439/breastcancer.2.015","url":null,"abstract":"","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91043283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-06DOI: 10.46439/breastcancer.2.010
A. Chichura, K. Yao
{"title":"Oncologist well-being in the era of COVID-19: A call to action","authors":"A. Chichura, K. Yao","doi":"10.46439/breastcancer.2.010","DOIUrl":"https://doi.org/10.46439/breastcancer.2.010","url":null,"abstract":"","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"131 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77613723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-06DOI: 10.46439/breastcancer.3.016
Rishika Singh, Nupur Singh, G. Vidal
This commentary discusses the case from the publication “Metastatic Triple Negative Breast Cancer with NTRK Gene Fusion on Tissue but not on ctDNA Molecular Profile.” This paper stresses the importance of molecular profiling to find characteristic mutations such as NTRK gene fusions which increase therapeutic options including tyrosine receptor kinase inhibitors such as Larotrectinib and entrectinib. The current profiling techniques are also discussed with both advantages and limitations discussed. Genomic testing in relation to current pharmaceutical therapies will shape the future of cancer diagnosis and treatment.
{"title":"NTRK fusions: A novel diagnostic and therapeutic methodology for cancer","authors":"Rishika Singh, Nupur Singh, G. Vidal","doi":"10.46439/breastcancer.3.016","DOIUrl":"https://doi.org/10.46439/breastcancer.3.016","url":null,"abstract":"This commentary discusses the case from the publication “Metastatic Triple Negative Breast Cancer with NTRK Gene Fusion on Tissue but not on ctDNA Molecular Profile.” This paper stresses the importance of molecular profiling to find characteristic mutations such as NTRK gene fusions which increase therapeutic options including tyrosine receptor kinase inhibitors such as Larotrectinib and entrectinib. The current profiling techniques are also discussed with both advantages and limitations discussed. Genomic testing in relation to current pharmaceutical therapies will shape the future of cancer diagnosis and treatment.","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76994742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-06DOI: 10.46439/breastcancer.2.014
S. Kadam, Tejaswini Kadam
{"title":"Sentinel lymph node biopsy in early breast cancer: A brief review","authors":"S. Kadam, Tejaswini Kadam","doi":"10.46439/breastcancer.2.014","DOIUrl":"https://doi.org/10.46439/breastcancer.2.014","url":null,"abstract":"","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79198482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号